Regeneron Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Cancer Antibody Drug Conjugates Market, Drugs Approval, Price, Sales & Clinical Trials
Antibody drug conjugates (ADCs) are a transformative class in cancer treatment, with 16 approved products and sales exceeding $10B in 2023. The market is expected to surpass $50B by 2030, driven by over 500 ADCs in clinical trials. Key players include Enhertu, Kadcyla, and Padcev, with significant sales in breast and lung cancers. The US and China lead the market, supported by robust R&D and regulatory environments.
Sanofi/Regeneron's Dupixent approved by EC for younger eosinophilic oesophagitis patients
Sanofi and Regeneron's Dupixent approved by EC for EoE in children aged 1-11 years, weighing at least 15kg, not controlled by conventional therapy. Dupixent showed 68% histological remission vs 3% placebo in phase 3 EoE KIDS trial, with sustained results up to one year.
EU approves Dupixent for treating eosinophilic esophagitis in young children
EMA approves Sanofi and Regeneron's Dupixent for treating eosinophilic esophagitis in children aged 1-11 years, marking the first EU approval for this age group. Dupixent, a monoclonal antibody targeting IL4 and IL13 pathways, showed efficacy in a phase 3 trial, with 68% of children achieving histological disease remission.
Sanofi, Regeneron Dupixent approved in EU for young children with eosinophilic esophagitis
Dupixent is now approved in the EU for treating eosinophilic esophagitis (EoE) in children aged 1-11, making it the first and only medicine indicated for this age group. The approval is based on the EoE KIDS phase 3 study, showing Dupixent's efficacy and safety in children similar to older EoE patients. Dupixent, an injection inhibiting IL4 and IL13 pathways, aims to improve the quality of life for young EoE patients.
EMA approves Dupixent for young EoE patients
EMA approved Sanofi/Regeneron’s Dupixent for EoE in children aged 1-11, based on EoE KIDS trial results. Dupixent is the first approved treatment for young EoE patients in EU, Canada, and US.
EMA approves Dupixent to treat eosinophilic esophagitis in children as young as one year
The European Medicines Agency approves Dupixent for eosinophilic esophagitis in children aged 1-11 years, making it the first treatment for this age group. The approval is based on the EoE KIDS phase 3 study showing Dupixent's efficacy and safety in children, with 68% achieving histological disease remission compared to 3% with placebo. Dupixent is administered subcutaneously and inhibits the IL4 and IL13 pathways, addressing type-2 inflammation.
Dupixent approved in the EU as the first and only medicine for young children with ...
The European Medicines Agency approved Dupixent for treating eosinophilic esophagitis in children aged one to 11 years, based on phase 3 data showing significant histological disease remission at 16 weeks, sustained up to one year. Dupixent is the first medicine in the EU indicated for these young patients, addressing a critical need where growth is crucial.
Assessing Regeneron Pharmaceuticals's Performance Against Competitors In ...
Regeneron Pharmaceuticals is compared against key competitors in the Biotechnology industry, revealing lower P/E, P/B, and P/S ratios suggesting potential undervaluation, but a low ROE indicating lower profitability efficiency. High EBITDA and gross profit levels show strong operational performance, while low revenue growth may be a concern.
First-of-a-kind EU approval granted for eosinophilic esophagitis medicine
EMA approves Dupixent (dupilumab) as the first treatment for young children with eosinophilic esophagitis in the EU, based on Phase III data showing 68% histological disease remission at 16 weeks, maintained up to one year. The treatment is for children weighing at least 15kg, inadequately controlled by conventional therapy.
Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Treating Eosinophilic Esophagitis in Children Aged 1 to 11
European Commission approves Dupixent for treating eosinophilic esophagitis in children aged 1 to 11, based on Phase 3 data showing significant histological disease remission at 16 weeks, sustained up to one year. Dupixent is the first medicine in the EU for this age group, addressing a critical need for young patients struggling with eating and growth.
© Copyright 2024. All Rights Reserved by MedPath